Discover Oncology

SCIE

國際簡稱：Discov Oncol 參考譯名：探索腫瘤學

主要研究方向：Medicine-Endocrinology, Diabetes and Metabolism 非預警期刊審稿周期： 5 Weeks

《探索腫瘤學》(Discover Oncology)是一本由Springer Nature出版的以Medicine-Endocrinology, Diabetes and Metabolism為研究特色的國際期刊，發表該領域相關的原創研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發現，旨在促進該學科領域科學信息的快速交流。該期刊是一本開放期刊，近三年沒有被列入預警名單。

4區中科院分區
Q2 JCR分區
229 年發文量
2.8 IF影響因子
開放是否OA
English 出版語言

Discover Oncology is an international journal dedicated to the field of oncology, aiming to provide a platform for researchers, clinicians, and students worldwide to exchange and share the latest scientific research achievements. This journal covers various aspects of oncology, including basic research, clinical research, drug development, diagnostic techniques, treatment strategies, and more. This journal is committed to publishing high-quality original research papers, review articles, case reports, technical reports, etc. to promote scientific progress and technological innovation in the field of oncology. At the same time, the magazine also focuses on education and training in oncology, regularly publishing relevant teaching articles and guidelines. As a professional, authoritative, and open oncology journal, it provides a high-quality academic exchange platform for researchers and clinical doctors worldwide.

[ 查看全部 ]

投稿咨詢加急咨詢

Discover Oncology期刊信息

ISSN：2730-6011
出版語言：English
是否OA：開放
E-ISSN：2730-6011
出版地區：Switzerland
是否預警：否
出版商：Springer Nature
開源占比：0.9951
Gold OA文章占比：99.54%
OA被引用占比：
出版國人文章占比：0
出版撤稿占比：
研究類文章占比：83.84%

Discover Oncology CiteScore評價數據（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數

2.4

0.715

0.527

學科類別	分區	排名	百分位
大類：Medicine 小類：Oncology	Q3	262 / 404	35%
大類：Medicine 小類：Endocrinology, Diabetes and Metabolism	Q3	165 / 244	32%
大類：Medicine 小類：Cancer Research	Q4	181 / 230	21%
大類：Medicine 小類：Endocrinology	Q4	103 / 128	19%
大類：Medicine 小類：Endocrine and Autonomic Systems	Q4	19 / 23	19%

名詞解釋：CiteScore 是衡量期刊所發表文獻的平均受引用次數，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據是期刊最近4年（含計算年度）的被引次數除以該期刊近四年發表的文獻數。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發表的文件的引用數量÷2019-2022年發布的文獻數量注：文獻類型包括：文章、評論、會議論文、書籍章節和數據論文。

Discover Oncology中科院評價數據

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	4區	ENDOCRINOLOGY & METABOLISM 內分泌學與代謝 ONCOLOGY 腫瘤學	4區 4區

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學科		小類學科
否	否	醫學	2區	ENDOCRINOLOGY & METABOLISM 內分泌學與代謝 ONCOLOGY 腫瘤學	2區 2區

Discover Oncology JCR評價數據（2023-2024年最新版）

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	97 / 186	48.1%
學科：ONCOLOGY	SCIE	Q2	157 / 322	51.4%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：ENDOCRINOLOGY & METABOLISM	SCIE	Q3	119 / 186	36.29%
學科：ONCOLOGY	SCIE	Q3	180 / 322	44.25%

Discover Oncology歷年數據統計

影響因子

中科院分區

Discover Oncology中國學者發文選摘

1、WDR76 regulates 5-fluorouracil sensitivity in colon cancer via HRAS
Author: Hu, Yunlong; Tan, Xiao; Zhang, Lin; Zhu, Xiang; Wang, Xiangyao

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00656-9
2、OncoVee (TM)-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study
Author: Zhang, Baonan; Li, Yuzhen; Zhu, Xiaodan; Chen, Zhe; Huang, Xiaona; Gong, Tingjie; Zheng, Weiwang; Bi, Zhenle; Zhu, Chenyang; Qian, Jingyi; Li, Xiaoqiang; Jin, Chunhui

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00661-y
3、Evaluation of predictive and prognostic value of androgen receptor expression in breast cancer subtypes treated with neoadjuvant chemotherapy
Author: Shi, Zhendong; Liu, Yingxue; Zhang, Shichao; Cai, Shuanglong; Liu, Xu; Meng, Jie; Zhang, Jin

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00660-z
4、Inhibition of secretory leukocyte protease inhibitor (SLPI) promotes the PUMA-mediated apoptosis and chemosensitivity to cisplatin in colorectal cancer cells
Author: Wei, Zhijiang; Liu, Guiying; Jia, Rufu; Zhang, Wei; Li, Li; Zhang, Yuanyuan; Wang, Zhijing; Bai, Xiyong

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-022-00535-9
5、The impact of postmastectomy radiotherapy on cT1-2N1 breast cancer patients with ypN0 after neoadjuvant chemotherapy: a retrospective study based on real-world data
Author: Dai, Yuran; Ma, Shishi; Lan, Ailin; Wang, Yihua; Wang, Yu; Jin, Yudi; Ding, Nan; Jiang, Linshan; Tang, Zhenrong; Yin, Xuedong; Peng, Yang; Liu, Shengchun

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-022-00609-8
6、Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway
Author: Wang, Ganggang; Zhang, Xin; Zhou, Zhijie; Song, Chao; Jin, Wenzhi; Zhang, Hao; Wu, Weixin; Yi, Yong; Cui, Hengguan; Zhang, Ping; Liu, Xinyu; Xu, Weiqiang; Shen, Xiaowei; Shen, Weixing; Wang, Xiaoliang

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00611-8
7、Thoracic SMARCA4-deficient undifferentiated tumor
Author: Jiang, Jiapeng; Chen, Zhixin; Gong, Jiali; Han, Na; Lu, Hongyang

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00639-w
8、TEM1 up-regulates MMP-2 and promotes ECM remodeling for facilitating invasion and migration of uterine sarcoma
Author: Wu, Chenghao; Sun, Wenhuizi; Shen, Dongsheng; Li, Huaifang; Tong, Xiaowen; Guo, Yi

Journal: DISCOVER ONCOLOGY. 2023; Vol. 14, Issue 1, pp. -. DOI: 10.1007/s12672-023-00613-6